nhsn 2015 rebaseline - tnpatientsafety.com resources/april... · 3/31/2017 · 2015 . 2015 (new)...
TRANSCRIPT
NHSN 2015 Rebaseline and TDH Updates Ashley Fell, MPH
Standardized Infection Ratio (SIR)
SIR = Observed O HAIsPredicted P HAIs
2
National Baseline Years
CLABSI and SSI
CAUTI
MRSA/CDI LabID
2006 2008 2010 2011 2009
All HAI Types: CLABSI, CAUTI, SSI,
MRSA/CDI LabID
2015
2015 (New) NHSN Baseline
Original NHSN Baseline 3
Rebaseline: Key Points • Benchmark updated to 2015
• SIRs may change
Better comparison to more current data!
4
CAUTI 25% SIR = 0.75
SSI 30% SIR = 0.70
CDI LabID 30% SIR = 0.70
MRSA LabID 50% SIR = 0.50
HHS 2020 Goals
CLABSI 50% SIR = 0.50
5 https://health.gov/hcq/prevent-hai-measures.asp
CLABSI SIR in Adult/Pediatric ICUs
0.75
0.39
6
CLABSI in Acute Care Hospitals
Unit Year No. of
Facs TN SIR
No. of Facs with Sig. LOW SIR
No. of Facs with Sig. HIGH SIR
Adult/Pediatric ICUs
2015 86 0.92 5 5
2016* 86 0.86 4 3
Adult/Pediatric Wards
2015 105 0.80 7 1
2016* 104 0.76 6 2
Neonatal ICUs 2015 25 0.92 0 0
2016* 25 0.63 2 0
7
*Preliminary 2016 data CLABSI HHS 2020 Goal: SIR = 0.5
CAUTI SIR in Adult/Pediatric ICUs
8
1.05
0.68
CAUTI in Acute Care Hospitals
Unit Year No. of
Facs TN SIR
No. of Facs with Sig. LOW SIR
No. of Facs with Sig. HIGH SIR
Adult/Pediatric ICUs
2015 86 1.04 3 5
2016* 86 0.92 4 4
Adult/Pediatric Wards
2015 105 0.67 5 1
2016* 104 0.68 6 1
9
*Preliminary 2016 data CAUTI HHS 2020 Goal: SIR = 0.75
Healthcare-Onset CDI SIR
10
CDI in Acute Care Hospitals
Year No. of Facs TN SIR No. of Facs with
Sig. LOW SIR No. of Facs with
Sig. HIGH SIR
2015 110 0.97 11 8
2016* 110 0.88 25 11
11
*Preliminary 2016 data CDI HHS 2020 Goal: SIR = 0.7
Healthcare-Onset MRSA Bacteremia SIR
12
Healthcare-Onset MRSA Bacteremia in TN
23% higher than US in 2015
13
MRSA in Acute Care Hospitals
Year No. of Facs TN SIR No. of Facs with
Sig. LOW SIR No. of Facs with
Sig. HIGH SIR
2015 110 1.23 0 6
2016* 110 1.33 3 6
14
*Preliminary 2016 data MRSA HHS 2020 Goal: SIR = 0.5
MRSA Prevention Resources
• SHEA – Strategies to Prevent MRSA Transmission and Infection in Acute Care Hospitals: 2014 Update
Available: https://doi.org/10.1017/S0899823X00193882
15
2015 Rebaseline Resources
• NHSN Rebaseline Webpage: https://www.cdc.gov/nhsn/2015rebaseline/index.html – Guide to the SIR – Rebaseline FAQs (General and HAI-specific FAQs) – CMS Related Resources – Other Resources include: recordings and slides from webinars,
applicable NHSN Newsletters
16
CRE Colonization Screening
CRE Colonization Screening • New! Offered by TDH through the
Antimicrobial Resistance Laboratory Network (ARLN) – Screen and detect CRE
– Prevent further transmission
– Increase laboratory capacity by providing service at no cost to facilities
18
CRE Colonization Screening • When to screen
– When a patient has confirmed CRE • Epi-linked contacts (roommates) • Consider broader screening depending on the following:
– Setting – Overlap in the length of stay – Level of care provided – Presence of risk factor (e.g. wound, incontinence)
– Discharged patients • Device exposures • Substantial overlap • High levels of care
19
CRE Colonization Screening
Interested in CRE colonization screening? Contact our team at [email protected] to help determine if a CRE case at your facility meets colonization screening criteria
20
CRE Colonization Screening- Specimen Flow
21
H
SPHL
TDH
Swabs from CR+
patient contacts
CR+
TDH HAI Team
Antimicrobial Use Tracking Options
Stewardship Training Incentive for Pharmacists
• Reimbursement available for pharmacists who complete stewardship training through SIDP or MAD-ID and successfully begin AU module reporting with TDH data sharing
23
NHSN Structure
NHSN
Patient Safety Component
Device-Associated Module
Procedure-Associated
Module
MDRO/CDI Module
Antimicrobial Use and Resistance
Module
Antimicrobial Use Option
Antimicrobial Resistance Option
Healthcare Personnel Safety
Component
Biovigilance Component
Long-Term Care Component
Dialysis Component
NHSN Antimicrobial Use and Resistance (AUR) Module • Released in 2011 • Provides mechanism to report and analyze antimicrobial
usage as part of facility-based antimicrobial stewardship efforts – Facility-wide – Unit-based
• Currently voluntary – ~232 facilities in 40 states reporting (Feb 2017) – 4 reporting in Tennessee, including 1 to both AU and
AR modules – One option for Public Health Registry reporting for
Meaningful Use Stage 3
25
NHSN AUR Module (cont.)
• Requirements to report: – Electronic Medication Administration Record (eMAR), or – Bar Coding Medication Administration (BCMA) systems
• AND – Ability to collect and package data using HL7 standardized
format (Clinical Document Architecture) – List of participating vendors: http://www.sidp.org/aurvendors or
“homegrown” methods
26
NHSN AU Required Metrics
• Monthly aggregate, summary-level data – FACWIDEIN (All units) – Medical and Surgical Wards/ICU – Adult vs. Pediatric Units
• Numerator: Antimicrobial Therapy (DOT) – 89 Antibiotics (IV, IM, Oral, Inhaled) – See CDC Antimicrobial Use and Resistance Module Protocol
Appendix B for Full List • https://www.cdc.gov/nhsn/pdfs/pscmanual/11pscaurcurrent.pdf
• Denominator – Days Present (NOT Patient Days) – Admissions
27
Interim Tracking Options
• TDH AU Point Prevalence Survey – Easily set up – Quick data pull, usually on monthly basis – Receive quarterly report with comparisons to other
participating facilities
• Long-term Care version under development to support and align with new Joint Commission Antimicrobial Stewardship Standard
28
Antibiotic Use Reporting
• Started in 2014 • Offers an interim way to
fulfill CDC Core Elements of Tracking and Reporting
• Metric: Number of patients on antibiotics/census data – Different from NHSN
• 29 institutions have reported at least once into survey
• ~10-15 do so routinely
• Q3-2016 Data
Antimicrobial Stewardship Recommendations, Adopted by THA Board in October 2015
1. Hospital demonstration of commitment to antibiotic stewardship via a written statement of support and consideration of dedicated pharmacy, clinician and IT staff time for antibiotic stewardship activities
2. All hospitals commit to reporting to the National Healthcare Safety Network (NHSN) antimicrobial use and resistance modules within specified timeframes
3. All hospitals commit to a policy requiring documentation of indications for antibiotic therapy
Antimicrobial Stewardship Recommendations, THA Board Adopted (October 2015)
4. All hospitals commit to implementing a policy requiring an “antibiotic review” at 48-72 hours to allow for appropriate review of clinical indication of need, response and any therapeutic revisions that might be appropriate
5. Participation by hospitals in an antibiotic stewardship collaborative to encourage best practice / lessons learned sharing, and development of appropriate educational programing, as well as any other steps or activities that would assist with antibiotic stewardship
TDH AU Survey Questions
• For sample copy of survey or report:
Contact Chris Evans, PharmD [email protected] or [email protected] 615-532-6604
32
Injectable Drug Diversion in
Healthcare Settings
2015 Newsweek Cover Story
http://www.newsweek.com/2015/06/26/traveler-one-junkies-harrowing-journey-across-america-344125.html
TDH Goals
• Support facility prevention efforts – 2017 ASHP Guidelines on Preventing Diversion of
Controlled Substances • Encourage more uniform response to suspected
injectable drug diversion including: – Written protocols and identified team members – Immediate testing for bloodborne pathogens (HIV,
HepB, HepC) following needlestick protocols – Prompt notification of TDH HAI group if positive per
outbreak reporting rules – Prompt reporting to licensing board – Consistent “not eligible for re-hire” response
Am J Health-Syst Pharm. 2017; 74:e10- 33
Ongoing TDH Efforts
• Improved coordination with Health Boards • Engaging stakeholders
– Health Board Investigators Fall 2017 – THA Quality Committee March 2017 – TnPAP director April 2017 – TMF director upcoming – National toolkit for State Health Departments under development
• What can you do?
Ask what your facility is doing to prevent diversion and respond swiftly and appropriately!
36
Injectable Drug Diversion Questions
• For additional questions or speaking requests:
Pam Talley MD, MPH [email protected] or [email protected] 615-532-6821
37
Contact Us
TDH HAI Team: [email protected]
(615) 741-7247
For more information about CRE Colonization
Screening: [email protected]
38